CALR and neoplasm: In 2015, Garg et al. used publicly available datasets that comprised patients with various cancer types to assess calreticulin expression levels in pre-treatment tumor tissue samples and showed that at least a subset of patients of various cancer types have low tumoral expression of calreticulin [38].